Leukemia: Clinical Trials

271 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

271 unknown. 271 Phase 1, 135 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1271Unknown 271
Phase 2135Unknown 135

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 271 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
DFP-10917, Venetoclax - Leukemia, Myeloid, Acute
Phase 1 / Phase 2UnknownDelta-Fly Pharma, Inc.392024-06-122025-09-03
Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
iPSC-NK cells - AML, Adult
Phase 1UnknownZhejiang University242024-04-302024-04-18
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
INS19 CAR-T Cells - Leukemia, B-cell
Phase 1UnknownBeijing Immunochina Medical Science & Technology Co., Ltd.122024-01-152024-01-17
Safety and Efficacy Evaluation of Next-generation CD19-UCART
CD19-UCART - Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
Phase 1UnknownBioray Laboratories202023-12-202023-01-27
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
Blinatumomab - Acute Lymphoblastic Leukemia
Phase 1UnknownZhejiang University312023-11-162023-11-09
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia
Phase 1 / Phase 2UnknownInstitute of Hematology & Blood Diseases Hospital, China422023-10-302023-11-02
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 / Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.1072023-10-112023-10-23
Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia
CLL1 CAR-NK cell injection - AML, Adult
Phase 1UnknownZhejiang University242023-09-102023-09-07
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
TQB2928 Injection + Azacitidine for injection - Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.482023-09-012023-09-06
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
NTQ2494 tablet - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1UnknownNanjing Chia-tai Tianqing Pharmaceutical722023-08-072023-09-22
A Study of TQB3454 Tablets in Patients With Blood Tumors
TQB3454 Tablets - Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1 / Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.802023-07-102024-01-23
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
Anti-CD19 Autologous CAR-T Cell Infusion - B-Cell Leukemia, B-Cell Lymphoma
Phase 1 / Phase 2Unknown920th Hospital of Joint Logistics Support Force of People's Liberation Army of China602023-07-012023-07-11
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
BC3402, Azacitidine - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Phase 1UnknownBiocity Biopharmaceutics Co., Ltd.322023-06-182023-08-01
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Allogeneic T cell progenitors, cultured ex-vivo - Hematological Malignancies
Phase 1 / Phase 2UnknownSmart Immune SAS402023-06-062023-09-25
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
FCTX-CL19-1 (Tarcidomgen Kimleucel) - Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL)
Phase 1UnknownFamiCordTx62023-05-242024-09-19
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
RC1012 injection (allo-DNT cells) - Acute Myeloid Leukemia
Phase 1 / Phase 2UnknownGuangdong Ruishun Biotech Co., Ltd722023-05-042023-05-19
A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.
combination of venetoclax and HAA regimen - Acute Myeloid Leukemia, Venetoclax
Phase 1 / Phase 2UnknownZePing Zhou452023-04-012023-06-08
Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly
Venetoclax in Combination With Azacitidine and HA Regimen - Acute Myeloid Leukemia
Phase 1 / Phase 2UnknownZePing Zhou452023-04-012023-07-18
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Anti-CD19-CAR - Leukemia
Phase 1UnknownKecellitics Biotech Company Ltd1002023-02-012022-12-01
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
umbilical cord derived mesenchymal stem cells - Hematologic Neoplasms, Neutropenia
Phase 1 / Phase 2UnknownUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology1812023-01-012023-01-05

Showing 20 of 271. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (115)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (69)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (45)  ·  Lymphoma (44)  ·  Recurrence (34)  ·  Myelodysplastic Syndromes (32)  ·  Lymphoma, Non-Hodgkin (27)  ·  Lymphoma, B-Cell (25)  ·  Leukemia, B-Cell (22)  ·  Lymphoma, Large B-Cell, Diffuse (21)  ·  Lymphoma, Mantle-Cell (18)  ·  Lymphoma, Follicular (17)  ·  Burkitt Lymphoma (16)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (14)

Broader conditions

Hemic and Lymphatic Diseases (271)  ·  Hematologic Diseases (270)  ·  Neoplasms by Histologic Type (270)  ·  Neoplasms (267)  ·  Immune System Diseases (157)  ·  Immunoproliferative Disorders (156)  ·  Lymphoproliferative Disorders (155)  ·  Lymphatic Diseases (154)  ·  Leukemia, Lymphoid (126)  ·  Leukemia, Myeloid (122)  ·  Pathologic Processes (94)  ·  Pathological Conditions, Signs and Symptoms (94)  ·  Disease Attributes (89)  ·  Lymphoma (59)

Interventions

Cyclophosphamide (21)  ·  fludarabine (21)  ·  Cytarabine (13)  ·  Immunotherapy, Adoptive (12)  ·  venetoclax (9)  ·  Azacitidine (7)  ·  Sensitivity and Specificity (6)  ·  Antigens, CD19 (5)  ·  Decitabine (5)  ·  Busulfan (4)  ·  Etoposide (4)  ·  fludarabine phosphate (4)  ·  Alemtuzumab (3)  ·  Arsenic Trioxide (3)  ·  Biological Therapy (3)

Sponsors

Chinese PLA General Hospital (10)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (8)  ·  Chongqing Precision Biotech Co., Ltd (7)  ·  PersonGen BioTherapeutics (Suzhou) Co., Ltd. (7)  ·  Hebei Senlang Biotechnology Inc., Ltd. (6)  ·  Southwest Hospital, China (6)  ·  The First Affiliated Hospital of Soochow University (5)  ·  Zhejiang University (5)  ·  iCell Gene Therapeutics (5)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (4)  ·  Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (4)  ·  The Affiliated Hospital of the Chinese Academy of Military Medical Sciences (4)  ·  Wuhan Sian Medical Technology Co., Ltd (4)  ·  Affiliated Hospital to Academy of Military Medical Sciences (3)  ·  Beijing Doing Biomedical Co., Ltd. (3)

Countries

China (149)  ·  United States (41)  ·  France (10)  ·  Germany (10)  ·  Australia (9)  ·  Canada (7)  ·  Italy (7)  ·  Poland (7)  ·  South Korea (6)  ·  United Kingdom (6)  ·  Belgium (5)  ·  Russia (5)  ·  Singapore (4)  ·  Brazil (3)  ·  Israel (3)

Top investigators

Cheng Qian, MD, PhD (6)  ·  Cheng Qian, PhD (6)  ·  Heng Mei, M.D., Ph.D (4)  ·  He Huang, MD (3)  ·  Sanbin Wang, MD (3)  ·  Xiaowen Tang, Ph.D (3)  ·  Gerald L. DeNardo, MD (2)  ·  Heng Mei, M.D. Ph.D (2)  ·  Hongyu Zhang, MD/PhD (2)  ·  Lin Yang, Ph.D. (2)  ·  Olga Aleinikova, MD, Prof (2)  ·  Peihua Lu, MD (2)  ·  Peihua Lu, PhD&MD (2)

Results publications

PMID 28054442, PMID 34515338, PMID 40195173, PMID 35126471, PMID 35799791, PMID 42826832, PMID 10632319, PMID 15016963, PMID 16564913, PMID 18172005, PMID 18596230, PMID 18616528, PMID 18794884, PMID 20015886, PMID 20371346, PMID 20626398, PMID 20959411, PMID 21791425, PMID 22589701, PMID 23673863, PMID 23876833, PMID 24311149, PMID 24450857, PMID 24450858, PMID 24488563, PMID 24497570, PMID 24615776, PMID 24615777, PMID 24641416, PMID 25174587, PMID 25394714, PMID 25444722, PMID 25621950, PMID 25631767, PMID 25682597, PMID 25805929, PMID 25983002, PMID 26376137, PMID 26497198, PMID 26687796, PMID 26779484, PMID 26819050, PMID 27347147, PMID 27579615, PMID 27716819, PMID 27887660, PMID 27916294, PMID 28039295, PMID 28161329, PMID 28280089

NIH funding

2009 (1), 2014 (1), 2016 (1), 2019 (1), P30CA016672 (1), P30CA060553 (1)